Annexin Pharmaceuticals AB

Developing Annexin A5 protein to treat vascular, inflammatory, and cancerous diseases.

ANNX | ST

Overview

Corporate Details

ISIN(s):: SE0009664154
LEI:: 5493000JP703HGPJEX27
Country:: Sweden
Address:: KAMMAKARGATAN 48, 111 60 Stockholm
Website:: https://annexinpharma.com/
Sector:: Manufacturing
Industry:: Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Annexin Pharmaceuticals AB is a clinical-stage biotechnology company focused on the therapeutic protein Annexin A5. The company's lead drug candidate, ANXV, is a recombinant human Annexin A5 that targets phosphatidylserine (PS), a lipid exposed on the surface of stressed or damaged cells. By binding to PS, ANXV acts as a cell protector and immunomodulator, counteracting tissue injury and regulating immune responses. The company's primary focus is on developing ANXV for indications with significant unmet medical needs, including Retinal Vein Occlusion (RVO), for which it is currently in Phase 2 clinical trials, and oncology. ANXV has potential as a first-in-class treatment across a broad range of vascular, inflammatory, and cancerous diseases.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Bulk Actions:

	Date	Filing	Language	Size	Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Annexin Pharmaceuticals AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Annexin Pharmaceuticals AB

This data is available as part of our premium data solutions. Contact our team for access.

Request This Data

Need More History? Access decades of standardized financials for Annexin Pharmaceuticals AB via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
Cannovum Cannabis AG Importer & producer of medical cannabis, expanding into recreational cultivation infrastructure.	Germany	27N0
Cantourage Group SE A European platform producing and distributing medical cannabis products to pharmacies.	Germany	HIGH
CAREGEN CO.,LTD. Develops patented peptides and growth factors for medical aesthetics, pharma, and anti-aging markets.	South Korea	214370
CELADON PHARMACEUTICALS PLC Vertically integrated pharma developing cannabis medicines for chronic pain.	United Kingdom	CEL
Celemics, Inc. Develops custom NGS panels and bioinformatics for research and clinical diagnostics.	South Korea	331920
Cellbion Co., Ltd Develops & manufactures radiopharmaceuticals for cancer diagnosis and therapy.	South Korea	308430
CELL BIOTECH CO ., LTD A global biotech firm offering probiotic raw materials, OEM/ODM services, and consumer brands.	South Korea	049960
Cellectis Develops 'off-the-shelf' CAR T-cell cancer immunotherapies using TALEN® gene-editing.	France	ALCLS
Cellid Co., Ltd. Biotech firm developing proprietary vaccine platforms for cancer and infectious diseases.	South Korea	299660
Cellromax Science Co., Ltd. Develops health foods, derma-cosmetics, and OTC drugs for pharmacies and online channels.	South Korea	471820